Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene delivery platform SVac. Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.
“We are very pleased to work with TNO”, said Ben van Leent, CEO of Amarna Therapeutics. “We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases. The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated 40 billion Euro’s in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.”
“The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Last viewed contents
MHRA Issues GMP Certification to AMRI UK Facility
Neurobiology: Washing machine for the brain
Category:Jewish_medical_organizations
Mutating Hepatitis Viruses Make Drug Treatment More Difficult - Study paves the way for the next generation of active substances
Category:Branched-chain_amino_acids
Amanita_velosa
Diagnosis_of_Asperger_syndrome
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions - Major investments are expanding manufacturing capacity for life sciences products at 13 Cytiva and Pall Corporation sites helping to meet customer demand.
Experimental antibiotic treats deadly MRSA infection
A more effective hydrogel for healing wounds
David vs Goliath: How a small molecule can defeat asthma attacks
